Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models

Authors: Isabel S. Jerchel, Pascale Lejeune, Rita Lampignano, Alexander Walter, Ralf Lesche, Atanas Kamburov, Dominik Mumberg, Peter Ellinghaus, Oliver Politz, Sylvia Gruenewald

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-3080

Source: Full article